Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iodixanol
Drug ID BADD_D01178
Description Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.
Indications and Usage Iodixanol is a contrast agent during coronary angiography.
Marketing Status approved
ATC Code V08AB09
DrugBank ID DB01249
KEGG ID D01474
MeSH ID C044834
PubChem ID 3724
TTD Drug ID D0Y4YG
NDC Product Code 71806-222; 65219-381; 0407-2223; 65219-383; 0407-2222; 57884-0029
UNII HW8W27HTXX
Synonyms iodixanol | Visipaque | Visipaque Unique Softpac | iodixanol-320 | contrast media 2-5410-3
Chemical Information
Molecular Formula C35H44I6N6O15
CAS Registry Number 92339-11-2
SMILES CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(= C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin reaction23.03.03.013; 10.01.03.0190.035567%Not Available
Sneezing22.12.03.0240.160051%
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.010670%Not Available
Stridor22.04.02.0030.015649%
Stupor19.02.05.004; 17.02.04.007--Not Available
Subarachnoid haemorrhage24.07.04.004; 17.08.01.010; 12.01.10.0110.007113%Not Available
Swelling08.01.03.0150.158629%Not Available
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.0180.202732%Not Available
Swollen tongue07.14.02.003; 23.04.01.014; 10.01.05.0150.049082%Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.049794%
Tachycardia02.03.02.0070.074691%Not Available
Tachypnoea22.02.01.0140.014227%Not Available
Tension19.06.02.005--Not Available
Throat irritation22.12.03.029; 07.05.05.0370.101721%Not Available
Throat tightness22.12.03.031; 19.01.02.0050.087495%Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombosis24.01.01.006--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.0070.007113%Not Available
Transient ischaemic attack24.04.06.005; 17.08.04.0010.014227%
Tremor17.01.06.0020.049794%
Type I hypersensitivity10.01.03.0060.007113%Not Available
Unresponsive to stimuli17.02.05.0310.039124%Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.032010%
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria10.01.06.001; 23.04.02.0010.774648%
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene